Kenneth Westover, MD, PhD, Associate Professor of Radiation Oncology and Biochemistry

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Vibliome Therapeutics
    Topic:
    Early stage drug discovery
    Date added:
    Date updated:
    05/08/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Amgen
    Topic:
    KRAS G12C inhibitors
    Date added:
    Date updated:
    05/08/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Revolution Medicines
    Topic:
    KRAS inhibitors
    Date added:
    01/04/2022
    Date updated:
    05/08/2024
Return to 162 Thoracic Oncology Tumor Board Conference (042222)